Site icon pharmaceutical daily

Rune Labs Announces Formation of Scientific Advisory Board of Experts in Neuroscience and Biomedical Engineering

Carrolee Barlow, M.D., Ph.D. and Srikantan Nagarajan, Ph.D. join as scientific advisors

SAN FRANCISCO–(BUSINESS WIRE)–Rune Labs, a company using aggregated brain data to empower the development and delivery of precision medicines for neurodegenerative and psychiatric diseases, today announced the formation of a Scientific Advisory Board of leading experts in neuroscience and biomedical engineering.

“Since closing our seed financing in 2020, Rune Labs has made tremendous strides toward advancing our goal of bringing precision medicines to neurodegenerative disorders by making brain data useful at scale,” said Brian Pepin, founder and CEO, Rune Labs. “With the addition of Drs. Barlow and Nagarajan as scientific advisors, we are building a Scientific Advisory Board of world class neuroscientists and biomedical engineers whose deep knowledge and experience will help to guide us as we continue to build out our brain data platform and engage with academic collaborators and industry partnerships.”

Carrolee Barlow, M.D., Ph.D., and Srikantan Nagarajan, Ph.D., join as members of the Rune Labs Scientific Advisory Board. Dr. Barlow is a renowned expert in neuroscience and neurodegeneration and formerly served as Chief Executive Officer of the Parkinson’s Institute and Clinical Center. Dr. Nagarajan is an expert in biomedical engineering and integrative neuroscience. He is a Professor in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco.

“The genetic ambiguity of Parkinson’s Disease has made it difficult to develop treatments that target the underlying mechanisms of the disease,” said Dr. Barlow. “Rune Labs is using its brain data platform to help drug developers advance precision medicines for patients with Parkinson’s and other neurodegenerative diseases by identifying the functional changes unique to each patient to uncover hidden disease phenotypes and enable its partners to design better targeted therapies for patients. I look forward to applying my years of experience in neurodegeneration to advising the team at Rune Labs as they work to enable targeted treatment options for patients.”

“There is an enormous amount of brain data collected by neuromodulation devices, wearable devices, brain image scans and other sources,” said Dr. Nagarajan. “Rune Labs’ platform automates the labeling, ingestion, and indexing of brain data at scale to create an aggregate dataset. I am eager to lend my support and expertise to Rune Labs as they work in the intersection of applied data and neuroscience.”

Carrolee Barlow, M.D., Ph.D.

Dr. Barlow is a renowned expert in neuroscience, neurodegeneration and rare diseases whose work has spanned clinical care, laboratory and clinical research, academia, and industry. She is currently Chief Medical Officer of ESCAPE Bio and formerly served as Chief Executive Officer of the Parkinson’s Institute and Clinical Center where she led all aspects of basic research, clinical research, and clinical care, as well as formed partnerships with biotech and pharmaceutical companies.

Srikantan Nagarajan, Ph.D.

Srikantan Nagarajan, Ph.D., is an expert in biomedical engineering and integrative neuroscience and is focused on the development and refinement of multimodal structural and functional brain imaging and brain computer interfaces. He is a Professor in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco (UCSF) and has joint appointments in the Department of Bioengineering and Therapeutic Sciences and in the Department of Otolaryngology, Head and Neck Surgery. He also serves as the Director of the Biomagnetic Imaging Laboratory at UCSF.

About Rune Labs

Rune Labs, Inc. is empowering the development of precision medicines for Parkinson’s Disease and other neurodegenerative disorders by using its software platform to make brain data useful at scale. We partner with academic collaborators to optimize clinical care for patients and with biopharma and medtech companies to enable the development of targeted treatments for patients with brain diseases. www.runelabs.io

Contacts

MacDougall

Karen Sharma or Amanda Houlihan

ksharma@macbiocom.com or ahoulihan@macbiocom.com
781 235 3060

Exit mobile version